World OTC Sales Up 6.8% in 1996

3 November 1997

The world over-the-counter drug market rose 6.8% in 1996 by value toreach a total of $44.8 billion, according to Nicholas Hall, chairman and chief executive of Nicholas Hall & Co, speaking at the annual OTC News conference in London, UK.

The world market will grow 58% during 1996-2006 to reach $71 billion by the end of the period, Mr Hall forecast. The biggest growth, 142%, will be in Middle Eastern and Asian countries, rising from $2.9 billion to $7.1 billion, followed by 127% in central and eastern Europe, with sales up from $1.8 billion to $4.1 billion, and then the "Latina" markets, which are forecast to advance 97% in the period, from $2.6 billion to $5.1 billion. In contrast, Western Europe will grow 37% during the period, from $10.3 billion to $14.1 billion, while the US market will be up 36% from $12.9 billion to $17.5 billion, and Japan will rise 11%, from $6.7 billion to $7.4 billion, said Mr Hall.

1996's leading OTC markets were the USA, up 28.8%, Japan (15%), Germany (6.2%), France (4.8%) and South Korea (4.7%). The best emerging markets are Brazil, Indonesia, China, India and Russia, he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight